Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Net Cash Flow (2020 - 2025)

Summit Therapeutics (SMMT) has disclosed Net Cash Flow for 7 consecutive years, with -$13.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 218.55% year-over-year to -$13.3 million, compared with a TTM value of $120.3 million through Dec 2025, up 256.11%, and an annual FY2025 reading of $120.3 million, up 256.11% over the prior year.
  • Net Cash Flow was -$13.3 million for Q4 2025 at Summit Therapeutics, up from -$59.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $525.3 million in Q4 2022 and bottomed at -$578.1 million in Q1 2023.
  • Average Net Cash Flow over 5 years is $8.0 million, with a median of -$3.6 million recorded in 2021.
  • The sharpest move saw Net Cash Flow surged 6634.72% in 2022, then crashed 10024.15% in 2023.
  • Year by year, Net Cash Flow stood at -$8.0 million in 2021, then soared by 6634.72% to $525.3 million in 2022, then crashed by 90.98% to $47.4 million in 2023, then crashed by 76.36% to $11.2 million in 2024, then tumbled by 218.55% to -$13.3 million in 2025.
  • Business Quant data shows Net Cash Flow for SMMT at -$13.3 million in Q4 2025, -$59.3 million in Q3 2025, and $86.3 million in Q2 2025.